These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 25608663)

  • 1. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.
    Sia D; Losic B; Moeini A; Cabellos L; Hao K; Revill K; Bonal D; Miltiadous O; Zhang Z; Hoshida Y; Cornella H; Castillo-Martin M; Pinyol R; Kasai Y; Roayaie S; Thung SN; Fuster J; Schwartz ME; Waxman S; Cordon-Cardo C; Schadt E; Mazzaferro V; Llovet JM
    Nat Commun; 2015 Jan; 6():6087. PubMed ID: 25608663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma.
    Li F; Peiris MN; Donoghue DJ
    Cytokine Growth Factor Rev; 2020 Apr; 52():56-67. PubMed ID: 31899106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
    Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
    Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
    Chong DQ; Zhu AX
    Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study.
    Sasaki M; Sato Y; Nakanuma Y
    Virchows Arch; 2024 Jun; 484(6):915-923. PubMed ID: 38532197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
    Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
    J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas.
    Pu X; Ye Q; Cai J; Yang X; Fu Y; Fan X; Wu H; Chen J; Qiu Y; Yue S
    Cell Death Dis; 2021 Mar; 12(3):256. PubMed ID: 33692336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
    Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
    PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma.
    Tsujie M; Iwai T; Kubo S; Ura T; Hatano E; Sakai D; Takeda Y; Kaibori M; Kobayashi T; Katanuma A; Katayose Y; Fukase K
    Jpn J Clin Oncol; 2021 May; 51(6):911-917. PubMed ID: 33822966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.
    Kendre G; Marhenke S; Lorz G; Becker D; Reineke-Plaaß T; Poth T; Murugesan K; Kühnel F; Woller N; Wirtz RM; Pich A; Marquardt JU; Saborowski M; Vogel A; Saborowski A
    Hepatology; 2021 Sep; 74(3):1357-1370. PubMed ID: 33709535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.
    Plum PS; Hess T; Bertrand D; Morgenstern I; Velazquez Camacho O; Jonas C; Alidousty C; Wagner B; Roessler S; Albrecht T; Becker J; Richartz V; Holz B; Hoppe S; Poh HM; Chia BKH; Chan CX; Pathiraja T; Teo AS; Marquardt JU; Khng A; Heise M; Fei Y; Thieme R; Klein S; Hong JH; Dima SO; Popescu I; Hoppe-Lotichius M; Buettner R; Lautem A; Otto G; Quaas A; Nagarajan N; Rozen S; Teh BT; Goeppert B; Drebber U; Lang H; Tan P; Gockel I; Schumacher J; Hillmer AM
    Clin Transl Med; 2024 Jun; 14(6):e1723. PubMed ID: 38877653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
    DiPeri TP; Zhao M; Evans KW; Varadarajan K; Moss T; Scott S; Kahle MP; Byrnes CC; Chen H; Lee SS; Halim AB; Hirai H; Wacheck V; Kwong LN; Rodon J; Javle M; Meric-Bernstam F
    J Hepatol; 2024 Feb; 80(2):322-334. PubMed ID: 37972659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma.
    Neumann O; Lehmann U; Bartels S; Pfarr N; Albrecht T; Ilm K; Christmann J; Volckmar AL; Goldschmid H; Kirchner M; Allgäuer M; Walker M; Kreipe H; Tannapfel A; Weichert W; Schirmacher P; Kazdal D; Stenzinger A
    J Pathol Clin Res; 2023 Mar; 9(2):100-107. PubMed ID: 36635225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR2 Inhibition in Cholangiocarcinoma.
    Vogel A; Segatto O; Stenzinger A; Saborowski A
    Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
    Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population.
    Pu XH; Ye Q; Yang J; Wu HY; Ding XW; Shi J; Mao L; Fan XS; Chen J; Qiu YD; Huang Q
    Hum Pathol; 2018 Jun; 76():100-109. PubMed ID: 29514108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
    Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
    Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 19. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
    Arai Y; Totoki Y; Hosoda F; Shirota T; Hama N; Nakamura H; Ojima H; Furuta K; Shimada K; Okusaka T; Kosuge T; Shibata T
    Hepatology; 2014 Apr; 59(4):1427-34. PubMed ID: 24122810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
    Saborowski A; Vogel A; Segatto O
    Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.